menu
    • menu

    Company profile for AbFero Pharmaceuticals

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Abfero Pharmaceuticals Inc. is a clinical stage pharmaceutical company focused exclusively on iron as a therapeutic target. Our mission is to develop best-in-class oral iron chelators for the treatment of diseases of iron overload. Patients with systemic iron overload due to transfusions or genetic conditions are at risk for severe organ damage and death. In addition, iron accumulation in the retina and brain are associated wi...
    Abfero Pharmaceuticals Inc. is a clinical stage pharmaceutical company focused exclusively on iron as a therapeutic target. Our mission is to develop best-in-class oral iron chelators for the treatment of diseases of iron overload. Patients with systemic iron overload due to transfusions or genetic conditions are at risk for severe organ damage and death. In addition, iron accumulation in the retina and brain are associated with a number of retinal and neurologic diseases leading to vision loss, neurodegeneration, and other debilitating conditions. Our lead, brain-penetrant small molecule SP-420 may prove an important addition

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AbFero PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Boston, Massachusetts
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.abferopharmaceuticals.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/abfero-pharmaceuticals?trk=public_profile_topcard_current_company
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharmacosmos is betting $225M on a new potential solution for that
    Pharmacosmos is betting $225M on a new potential solution for that

    11 Nov 2021

    // Nicole DeFeudis ENDPTS

    https://endpts.com/too-much-iron-pharmacosmos-is-betting-225m-on-a-new-potential-solution-for-that/

    Nicole DeFeudis ENDPTS
    11 Nov 2021
    Share Share
    AbFero Announces Initiation Of Phase 1 Study For Lead Iron Chelator
    AbFero Announces Initiation Of Phase 1 Study For Lead Iron Chelator

    23 Feb 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/abfero-pharmaceuticals-announces-initiation-of-phase-1-study-for-lead-iron-chelator-301233582.html

    PRNEWSWIRE
    23 Feb 2021
    Share Share
    AbFero Pharmaceuticals Announces Funding From Cure Parkinson's For Lead SP-420
    AbFero Pharmaceuticals Announces Funding From Cure Parkinson's For Lead SP-420

    17 Feb 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/abfero-pharmaceuticals-announces-funding-from-cure-parkinsons-for-lead-compound-sp-420-301229674.html

    PRNEWSWIRE
    17 Feb 2021
    Share Share
    AbFero to Receive € 2M Eurostars Funding for Parkinson's Disease Therapy
    AbFero to Receive € 2M Eurostars Funding for Parkinson's Disease Therapy

    01 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/abfero-to-receive--2m-eurostars-funding-for-parkinsons-disease-therapy-301182276.html

    PRNEWSWIRE
    01 Dec 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search